Details for Patent: 8,541,575

Which drugs does patent 8,541,575 protect, and when does it expire?

Patent 8,541,575 protects BRAFTOVI and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 8,541,575

Title:	3,4-diarylpyrazoles as protein kinase inhibitors
Abstract:	3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. ##STR00001##
Inventor(s):	Pulici; Maurizio (Caponago, IT), Zuccotto; Fabio (Milan, IT), Badari; Alessandra (Vedano al Lambro, IT), Nuvoloni; Stefano (Genoa, IT), Cervi; Giovanni (Como, IT), Traquandi; Gabriella (Milan, IT), Biondaro; Sonia (Ronca, IT), Trifiro'; Paolo (Genoa, IT), Marchionni; Chiara (Milan, IT), Modugno; Michele (Cernusco sul Naviglio, IT)
Assignee:	Nerviano Medical Sciences S.R.L. (Nerviano, IT)
Application Number:	13/054,853
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Device;

Drugs Protected by US Patent 8,541,575

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No			Y	Y		TREATMENT OF MELANOMA
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes			Y	Y		TREATMENT OF MELANOMA
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes			Y	Y		BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes			Y	Y		BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

Foreign Priority and PCT Information for Patent: 8,541,575

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08161076	Jul 24, 2008

PCT Information
PCT Filed	July 23, 2009	PCT Application Number:	PCT/EP2009/059506
PCT Publication Date:	January 28, 2010	PCT Publication Number:	WO2010/010154

International Family Members for US Patent 8,541,575

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E557015
Australia	2009273197
Brazil	PI0916356
Canada	2731146